JP2010500413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500413A5 JP2010500413A5 JP2009524736A JP2009524736A JP2010500413A5 JP 2010500413 A5 JP2010500413 A5 JP 2010500413A5 JP 2009524736 A JP2009524736 A JP 2009524736A JP 2009524736 A JP2009524736 A JP 2009524736A JP 2010500413 A5 JP2010500413 A5 JP 2010500413A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidinyl
- imidazol
- biphenylyl
- oxo
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 899
- -1 carboxy, formyl Chemical group 0.000 claims 290
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 235
- 229910052757 nitrogen Inorganic materials 0.000 claims 84
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 77
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 67
- 150000003839 salts Chemical class 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 37
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 36
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 31
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 26
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims 16
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 15
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 13
- BQKLBHZGHOKWSR-BTSKBWHGSA-N (2r)-2-morpholin-4-yl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H]2OCCC2)C=2C=CC=CC=2)CCOCC1 BQKLBHZGHOKWSR-BTSKBWHGSA-N 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- PQJFJRGZSZKPTF-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O.COC(N)=O PQJFJRGZSZKPTF-UHFFFAOYSA-N 0.000 claims 7
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 6
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 108010050904 Interferons Proteins 0.000 claims 6
- 102000014150 Interferons Human genes 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 239000004202 carbamide Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 229950003188 isovaleryl diethylamide Drugs 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims 4
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 4
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 4
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 claims 4
- GXHAENUAJYZNOA-UHFFFAOYSA-N oxolane-2-carboxamide Chemical compound NC(=O)C1CCCO1 GXHAENUAJYZNOA-UHFFFAOYSA-N 0.000 claims 4
- 229960000329 ribavirin Drugs 0.000 claims 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- UMPWFNPLHSVRAN-UHFFFAOYSA-N 2-(diethylamino)-2-phenylacetaldehyde Chemical compound CCN(CC)C(C=O)C1=CC=CC=C1 UMPWFNPLHSVRAN-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229940049953 phenylacetate Drugs 0.000 claims 3
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 3
- NGACNFMXLHHFTI-JPYDVTDNSA-N (2r)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenyl-2-piperidin-1-ylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H]2OCCC2)C=2C=CC=CC=2)CCCCC1 NGACNFMXLHHFTI-JPYDVTDNSA-N 0.000 claims 2
- XUXLCKDCNOQMOC-ATUXXYJQSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-2-(trifluoromethyl)phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)C)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C(=C2)C(F)(F)F)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 XUXLCKDCNOQMOC-ATUXXYJQSA-N 0.000 claims 2
- IUKDDNWJLHYBGC-ATUXXYJQSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)C)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 IUKDDNWJLHYBGC-ATUXXYJQSA-N 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- KXRRLLSJROBMBU-IIOWIJGZSA-N 2-(7-azabicyclo[2.2.1]heptan-7-yl)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[2-(7-azabicyclo[2.2.1]heptan-7-yl)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)C(N1C2CCC1CC2)C=1C=CC=CC=1)C(=O)C(N1C2CCC1CC2)C1=CC=CC=C1 KXRRLLSJROBMBU-IIOWIJGZSA-N 0.000 claims 2
- AOGFRXVTKLIGBI-UHFFFAOYSA-N 2-(dimethylamino)-2-phenylacetaldehyde Chemical compound CN(C)C(C=O)C1=CC=CC=C1 AOGFRXVTKLIGBI-UHFFFAOYSA-N 0.000 claims 2
- HVXUKFHYSAXUQR-KUKVWGSOSA-N 2-[(3s)-3-fluoropyrrolidin-1-yl]-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[2-[(3s)-3-fluoropyrrolidin-1-yl]-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1[C@@H](F)CCN1C(C=1C=CC=CC=1)C(=O)N1[C@H](C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)C(N2C[C@@H](F)CC2)C=2C=CC=CC=2)CCC1 HVXUKFHYSAXUQR-KUKVWGSOSA-N 0.000 claims 2
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- VSCSIVBMRODHIP-RRKGBCIJSA-N (2R)-2-hydroxy-1-(3-hydroxypyrrolidin-1-yl)-2-phenylethanone Chemical compound O=C([C@H](O)C=1C=CC=CC=1)N1CCC(O)C1 VSCSIVBMRODHIP-RRKGBCIJSA-N 0.000 claims 1
- CTRPRHJEFXXKTO-ACHIHNKUSA-N (2S)-2-[1-tert-butyl-5-[4-[4-[2-[(2S)-1-phenylmethoxycarbonylpyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-4-(trifluoromethyl)imidazol-2-yl]pyrrolidine-1-carboxylic acid Chemical compound CC(C)(C)N1C(=NC(=C1C2=CC=C(C=C2)C3=CC=C(C=C3)C4=CN=C(N4)[C@@H]5CCCN5C(=O)OCC6=CC=CC=C6)C(F)(F)F)[C@@H]7CCCN7C(=O)O CTRPRHJEFXXKTO-ACHIHNKUSA-N 0.000 claims 1
- NJGTUGMFRWNXBW-URXFXBBRSA-N (2S)-2-[5-[2-fluoro-4-[4-[2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCC[C@H]1C1=NC=C(C=2C(=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2NCCC2)F)N1 NJGTUGMFRWNXBW-URXFXBBRSA-N 0.000 claims 1
- NQMOHQHKXWEJAE-ZEQRLZLVSA-N (2S)-2-[5-[4-[4-[2-[(2S)-1-carboxypyrrolidin-2-yl]-1H-imidazol-5-yl]-3-fluorophenyl]-2-fluorophenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCC[C@H]1C1=NC=C(C=2C(=CC(=CC=2)C=2C=C(F)C(C=3NC(=NC=3)[C@H]3N(CCC3)C(O)=O)=CC=2)F)N1 NQMOHQHKXWEJAE-ZEQRLZLVSA-N 0.000 claims 1
- KPOOTHVUARHMTR-ZEQRLZLVSA-N (2S)-2-[5-[4-[4-[2-[(2S)-1-carboxypyrrolidin-2-yl]-1H-imidazol-5-yl]-3-fluorophenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=C(F)C(C=3NC(=NC=3)[C@H]3N(CCC3)C(O)=O)=CC=2)N1 KPOOTHVUARHMTR-ZEQRLZLVSA-N 0.000 claims 1
- OEGGMPCANFOVSI-ZEQRLZLVSA-N (2S)-2-[5-[4-[4-[2-[(2S)-1-carboxypyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(O)=O)N1 OEGGMPCANFOVSI-ZEQRLZLVSA-N 0.000 claims 1
- KRSAYGSVMVDOPF-BTSKBWHGSA-N (2r)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenyl-2-pyrrolidin-1-ylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H]2OCCC2)C=2C=CC=CC=2)CCCC1 KRSAYGSVMVDOPF-BTSKBWHGSA-N 0.000 claims 1
- VOCZDPISQHKZSQ-LZCGGXSTSA-N (2r)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-4,4-difluoro-1-[(2r)-2-phenyl-2-piperidin-1-ylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-4,4-difluoropyrrolidin-1-yl]-2-phenyl-2-piperidin-1-ylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CC(C2)(F)F)C=2NC=C(N=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CC(F)(F)C2)C(=O)[C@H](N2CCCCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCCCC1 VOCZDPISQHKZSQ-LZCGGXSTSA-N 0.000 claims 1
- JCMKFTURXQEBOI-FTVGNFKQSA-N (2r)-1-[(2s,4s)-4-fluoro-2-[5-[4-[4-[2-[(2s,4s)-4-fluoro-1-[(2r)-2-phenyl-2-piperidin-1-ylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenyl-2-piperidin-1-ylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](C[C@@H](C2)F)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(C[C@@H](F)C2)C(=O)[C@H](N2CCCCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCCCC1 JCMKFTURXQEBOI-FTVGNFKQSA-N 0.000 claims 1
- KCRKCIONJOJIJF-JRTLPCBOSA-N (2r)-2-(4-hydroxy-4-methylpiperidin-1-yl)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(4-hydroxy-4-methylpiperidin-1-yl)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1CC(C)(O)CCN1[C@H](C=1C=CC=CC=1)C(=O)N1[C@H](C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](N2CCC(C)(O)CC2)C=2C=CC=CC=2)CCC1 KCRKCIONJOJIJF-JRTLPCBOSA-N 0.000 claims 1
- QCYJEPFMDGAYSD-LZCGGXSTSA-N (2r)-2-(diethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-2,5-difluorophenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(CC)CC)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=C(F)C=C(C(=C2)F)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(CC)CC)C=2C=CC=CC=2)=CC=CC=C1 QCYJEPFMDGAYSD-LZCGGXSTSA-N 0.000 claims 1
- GXTKKFXXMWRHTJ-LZCGGXSTSA-N (2r)-2-(diethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-3-fluorophenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(CC)CC)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2F)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(CC)CC)C=2C=CC=CC=2)=CC=CC=C1 GXTKKFXXMWRHTJ-LZCGGXSTSA-N 0.000 claims 1
- UWAMWQMSHLVZIG-LZCGGXSTSA-N (2r)-2-(diethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(CC)CC)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(CC)CC)C=2C=CC=CC=2)=CC=CC=C1 UWAMWQMSHLVZIG-LZCGGXSTSA-N 0.000 claims 1
- RHJAPGNPPQBNKZ-JPYDVTDNSA-N (2r)-2-(diethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(diethylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one Chemical compound CCN(CC)[C@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](C(C)C)N(CC)CC)N1 RHJAPGNPPQBNKZ-JPYDVTDNSA-N 0.000 claims 1
- BIXCKKUISKNHQU-SFSFMBGESA-N (2r)-2-(diethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(diethylamino)propanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound CCN(CC)[C@H](C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](C)N(CC)CC)N1 BIXCKKUISKNHQU-SFSFMBGESA-N 0.000 claims 1
- HENITQMDQHJFFP-MUPJHJRRSA-N (2r)-2-(diethylamino)-1-[(2s,4s)-2-[5-[4-[4-[2-[(2s,4s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]-4-hydroxypyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-4-hydroxypyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(CC)CC)C(=O)N2C[C@@H](O)C[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2C[C@H](O)CN2C(=O)[C@H](N(CC)CC)C=2C=CC=CC=2)=CC=CC=C1 HENITQMDQHJFFP-MUPJHJRRSA-N 0.000 claims 1
- ZTVMKLVQIRLXRN-IYTFMMMVSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[4-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1-methylimidazol-4-yl]phenyl]phenyl]-1-methylimidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)C)C(=O)N2CCC[C@H]2C=2N(C)C=C(N=2)C2=CC=C(C=C2)C2=CC=C(C=C2)C=2N=C(N(C=2)C)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 ZTVMKLVQIRLXRN-IYTFMMMVSA-N 0.000 claims 1
- QQCXMZQNDLMMFL-ZTJXFJJRSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[3-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-4-methoxyphenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)C)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC(=CC=C2OC)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 QQCXMZQNDLMMFL-ZTJXFJJRSA-N 0.000 claims 1
- FGGHPRHSHSKDFY-WQNNDMHESA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-(2-naphthalen-1-ylacetyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@H](C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)CC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 FGGHPRHSHSKDFY-WQNNDMHESA-N 0.000 claims 1
- SZSNGJXSUGDHBS-IYTFMMMVSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-2-methylphenyl]-3-methylphenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)C)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C(=C2)C)C2=CC=C(C=C2C)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 SZSNGJXSUGDHBS-IYTFMMMVSA-N 0.000 claims 1
- FWSMGVFRTFQBND-SKQWTEPWSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-2-methylphenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)C)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C(=C2)C)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 FWSMGVFRTFQBND-SKQWTEPWSA-N 0.000 claims 1
- BDSIXINCAISMAK-IYTFMMMVSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-3-phenylpropanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-phenylpropan-1-one Chemical compound C([C@@H](N(C)C)C(=O)N1[C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)[C@@H](CC=1C=CC=CC=1)N(C)C)C1=CC=CC=C1 BDSIXINCAISMAK-IYTFMMMVSA-N 0.000 claims 1
- ZILFXIZLQOTHSA-DDADIKCBSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)propanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound CN(C)[C@H](C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](C)N(C)C)N1 ZILFXIZLQOTHSA-DDADIKCBSA-N 0.000 claims 1
- FWGCYCKXNMGIBF-YZBUDRBASA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[4-(dimethylamino)benzoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)CCN1C(=O)C1=CC=C(N(C)C)C=C1 FWGCYCKXNMGIBF-YZBUDRBASA-N 0.000 claims 1
- OSJQRQBAHSPLNB-XUTHUYCTSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[4-(hydroxymethyl)benzoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)CCN1C(=O)C1=CC=C(CO)C=C1 OSJQRQBAHSPLNB-XUTHUYCTSA-N 0.000 claims 1
- ZQWPLEWGQJOEIG-ZZDDQDSOSA-N (2r)-2-(dimethylamino)-1-[(2s,4s)-2-[5-[4-[4-[2-[(2s,4s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]-4-hydroxypyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-4-hydroxypyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)C)C(=O)N2C[C@@H](O)C[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2C[C@H](O)CN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 ZQWPLEWGQJOEIG-ZZDDQDSOSA-N 0.000 claims 1
- NWQCAAUPWUXELC-JPYDVTDNSA-N (2r)-2-(dimethylamino)-1-[(4r)-4-[5-[4-[4-[2-[(4r)-3-[(2r)-2-(dimethylamino)-2-phenylacetyl]-1,3-thiazolidin-4-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-1,3-thiazolidin-3-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)C)C(=O)N2CSC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CSCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 NWQCAAUPWUXELC-JPYDVTDNSA-N 0.000 claims 1
- LXAKRTGKWHMPJP-KWDKOVGYSA-N (2r)-2-(dimethylamino)-2-phenyl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-(3-pyrrolidin-1-ylbenzoyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]ethanone Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)CCN1C(=O)C(C=1)=CC=CC=1N1CCCC1 LXAKRTGKWHMPJP-KWDKOVGYSA-N 0.000 claims 1
- QACMRPXUCTZBOA-IWJNXRQDSA-N (2r)-2-(dimethylamino)-2-phenyl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-(5-phenylthiophene-2-carbonyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]ethanone Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)CCN1C(=O)C(S1)=CC=C1C1=CC=CC=C1 QACMRPXUCTZBOA-IWJNXRQDSA-N 0.000 claims 1
- WDBPQXUEJJCSSM-ZLBAHODBSA-N (2r)-2-(dipropylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dipropylamino)propanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound CCCN(CCC)[C@H](C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](C)N(CCC)CCC)N1 WDBPQXUEJJCSSM-ZLBAHODBSA-N 0.000 claims 1
- ASFUWJHTRWCQLF-IYTFMMMVSA-N (2r)-2-[ethyl(methyl)amino]-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-[ethyl(methyl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](N(C)CC)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)CC)C=2C=CC=CC=2)=CC=CC=C1 ASFUWJHTRWCQLF-IYTFMMMVSA-N 0.000 claims 1
- UAGSIMCUMTVTNA-GASGPIRDSA-N (2r)-2-amino-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one Chemical compound CC(C)[C@@H](N)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](N)C(C)C)N1 UAGSIMCUMTVTNA-GASGPIRDSA-N 0.000 claims 1
- HQDZRYUCSGSHCM-IZSXRKQISA-N (2r)-2-hydroxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-hydroxy-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-2-methylphenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](O)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2C)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](O)C=2C=CC=CC=2)=CC=CC=C1 HQDZRYUCSGSHCM-IZSXRKQISA-N 0.000 claims 1
- BYPMSKJLHSBHJD-CDBYGCFJSA-N (2r)-2-hydroxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-hydroxy-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](O)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](O)C=2C=CC=CC=2)=CC=CC=C1 BYPMSKJLHSBHJD-CDBYGCFJSA-N 0.000 claims 1
- IAHMCIMIFFMSLK-GASGPIRDSA-N (2r)-2-hydroxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-hydroxy-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one Chemical compound CC(C)[C@@H](O)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](O)C(C)C)N1 IAHMCIMIFFMSLK-GASGPIRDSA-N 0.000 claims 1
- SYMAFFKJYPWFHP-JPYDVTDNSA-N (2r)-2-hydroxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-hydroxy-3-phenylpropanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-phenylpropan-1-one Chemical compound C([C@@H](O)C(=O)N1[C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)[C@H](O)CC=1C=CC=CC=1)C1=CC=CC=C1 SYMAFFKJYPWFHP-JPYDVTDNSA-N 0.000 claims 1
- UFRPXKSFPYDVRA-SJWRPRNESA-N (2r)-2-hydroxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-hydroxypropanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound C[C@@H](O)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](C)O)N1 UFRPXKSFPYDVRA-SJWRPRNESA-N 0.000 claims 1
- QCIHCVATPVOJKG-XJDCEBINSA-N (2r)-2-hydroxy-1-[(2s,4r)-4-hydroxy-2-[5-[4-[4-[2-[(2s,4r)-4-hydroxy-1-[(2r)-2-hydroxy-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](O)C(=O)N2C[C@H](O)C[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](O)C=2C=CC=CC=2)=CC=CC=C1 QCIHCVATPVOJKG-XJDCEBINSA-N 0.000 claims 1
- UXBCVKLRKAKSSL-JPYDVTDNSA-N (2r)-2-methoxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-methoxy-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](OC)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](OC)C=2C=CC=CC=2)=CC=CC=C1 UXBCVKLRKAKSSL-JPYDVTDNSA-N 0.000 claims 1
- QFTOZIFOZMBEEH-LZCGGXSTSA-N (2r)-2-morpholin-4-yl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-morpholin-4-yl-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](N2CCOCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCOCC1 QFTOZIFOZMBEEH-LZCGGXSTSA-N 0.000 claims 1
- KTDHJRVKPDUSBY-JRTLPCBOSA-N (2r)-2-phenyl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-phenyl-2-piperidin-1-ylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-piperidin-1-ylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](N2CCCCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCCCC1 KTDHJRVKPDUSBY-JRTLPCBOSA-N 0.000 claims 1
- BGWGLHJWKQZPKG-LZCGGXSTSA-N (2r)-2-phenyl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-phenyl-2-pyrrolidin-1-ylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-pyrrolidin-1-ylethanone Chemical compound N1([C@@H](C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](N2CCCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 BGWGLHJWKQZPKG-LZCGGXSTSA-N 0.000 claims 1
- YOZBJKIABZDGPP-CBULZRFXSA-N (2r)-2-phenyl-2-piperidin-1-yl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-(2-thiophen-2-ylacetyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]ethanone Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)[C@H](N1CCCCC1)C=1C=CC=CC=1)C(=O)CC1=CC=CS1 YOZBJKIABZDGPP-CBULZRFXSA-N 0.000 claims 1
- IUKDDNWJLHYBGC-IWWWZYECSA-N (2s)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@H](N(C)C)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 IUKDDNWJLHYBGC-IWWWZYECSA-N 0.000 claims 1
- ZILFXIZLQOTHSA-UDRQUUIHSA-N (2s)-2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(dimethylamino)propanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound CN(C)[C@@H](C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](C)N(C)C)N1 ZILFXIZLQOTHSA-UDRQUUIHSA-N 0.000 claims 1
- AEVJCQZIZSAJLH-OBMDHMNCSA-N (2s)-2-(methylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methylamino)propanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound CN[C@@H](C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](C)NC)N1 AEVJCQZIZSAJLH-OBMDHMNCSA-N 0.000 claims 1
- KYQGKPDXJAVBEQ-DYGKRUFJSA-N (2s)-2-[benzyl(methyl)amino]-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-[benzyl(methyl)amino]propanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound CN([C@@H](C)C(=O)N1[C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)[C@H](C)N(C)CC=1C=CC=CC=1)CC1=CC=CC=C1 KYQGKPDXJAVBEQ-DYGKRUFJSA-N 0.000 claims 1
- NIBLWEFROMDHCM-ZQWQDMLBSA-N (2s)-2-cyclohexyl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-cyclohexyl-2-hydroxyacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-hydroxyethanone Chemical compound C1([C@H](O)C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](O)C2CCCCC2)CCCCC1 NIBLWEFROMDHCM-ZQWQDMLBSA-N 0.000 claims 1
- MIIUYAOLJFKCDB-SOAZDVDRSA-N (2s)-2-hydroxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-hydroxy-2-phenylpropanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylpropan-1-one Chemical compound C1([C@](C)(O)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@](O)(C)C=2C=CC=CC=2)=CC=CC=C1 MIIUYAOLJFKCDB-SOAZDVDRSA-N 0.000 claims 1
- IAHMCIMIFFMSLK-YDPTYEFTSA-N (2s)-2-hydroxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-hydroxy-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one Chemical compound CC(C)[C@H](O)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](O)C(C)C)N1 IAHMCIMIFFMSLK-YDPTYEFTSA-N 0.000 claims 1
- WQQMZBVPBSKVPV-CUPIEXAXSA-N (2s)-2-hydroxy-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-hydroxy-4-methylpentanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-4-methylpentan-1-one Chemical compound CC(C)C[C@H](O)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](O)CC(C)C)N1 WQQMZBVPBSKVPV-CUPIEXAXSA-N 0.000 claims 1
- AGGZMBJBJVDLHB-ATACATFBSA-N (4s)-4-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(4s)-2-oxo-1,3-oxazinane-4-carbonyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidine-1-carbonyl]-1,3-oxazinan-2-one Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)OCC1)C(=O)[C@@H]1CCOC(=O)N1 AGGZMBJBJVDLHB-ATACATFBSA-N 0.000 claims 1
- HANJVUROINGYGL-MUVIMXQCSA-N (4s,5r)-5-methyl-4-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(4s,5r)-5-methyl-2-oxo-1,3-oxazolidine-4-carbonyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidine-1-carbonyl]-1,3-oxazolidin-2-one Chemical compound C[C@H]1OC(=O)N[C@@H]1C(=O)N1[C@H](C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H]2[C@H](OC(=O)N2)C)CCC1 HANJVUROINGYGL-MUVIMXQCSA-N 0.000 claims 1
- SZPANMBAXSMUMO-GVYQIEHESA-N (5r)-5-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidine-1-carbonyl]pyrrolidin-2-one Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)CCN1C(=O)[C@H]1CCC(=O)N1 SZPANMBAXSMUMO-GVYQIEHESA-N 0.000 claims 1
- QTLXNQVEHAWKMY-NOBGTIEJSA-N (5s)-5-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidine-1-carbonyl]pyrrolidin-2-one Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(CC)CC)C=2C=CC=CC=2)CCN1C(=O)[C@@H]1CCC(=O)N1 QTLXNQVEHAWKMY-NOBGTIEJSA-N 0.000 claims 1
- BVHLIRXEHAFUKM-SNLXXZSDSA-N 1-[(1r)-2-[(2s,4r)-4-hydroxy-2-[5-[4-[4-[2-[(2s,4r)-4-hydroxy-1-[(2r)-2-(methylcarbamoylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]-3-methylurea Chemical compound C1([C@@H](NC(=O)NC)C(=O)N2C[C@H](O)C[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](NC(=O)NC)C=2C=CC=CC=2)=CC=CC=C1 BVHLIRXEHAFUKM-SNLXXZSDSA-N 0.000 claims 1
- PGNCMSVERQPZBR-JRTLPCBOSA-N 1-[(1r)-2-oxo-1-phenyl-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-phenyl-2-(pyridin-3-ylcarbamoylamino)acetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]ethyl]-3-pyridin-3-ylurea Chemical compound N([C@@H](C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@H](NC(=O)NC=1C=NC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)NC1=CC=CN=C1 PGNCMSVERQPZBR-JRTLPCBOSA-N 0.000 claims 1
- GTXLDAQLCOVOIO-SIEKYESCSA-N 1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2,2-diphenylethanone Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 GTXLDAQLCOVOIO-SIEKYESCSA-N 0.000 claims 1
- CQSPWJTYUHEUGB-AQVMEVBTSA-N 1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-piperidin-1-ylpropan-1-one Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)CCN1C(=O)CCN1CCCCC1 CQSPWJTYUHEUGB-AQVMEVBTSA-N 0.000 claims 1
- AGQUGDPUFVDBSQ-NSOVKSMOSA-N 1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-propanoylpyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound CCC(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)CC)N1 AGQUGDPUFVDBSQ-NSOVKSMOSA-N 0.000 claims 1
- VSVACLHEKVUUAG-URLMMPGGSA-N 1-[4-[4-[2-[(2S)-1-[(2R)-2-(methoxycarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]imidazole-4-carboxylic acid Chemical compound COC(=O)N[C@@H](C(=O)N1[C@@H](CCC1)C=1NC(=CN=1)C1=CC=C(C=C1)C1=CC=C(C=C1)N1C=NC(=C1)C(=O)O)C1=CC=CC=C1 VSVACLHEKVUUAG-URLMMPGGSA-N 0.000 claims 1
- IMNIHXTVVDWOOR-JRTLPCBOSA-N 1-cyclopentyl-3-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(cyclopentylcarbamoylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]urea Chemical compound N([C@@H](C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@H](NC(=O)NC1CCCC1)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)NC1CCCC1 IMNIHXTVVDWOOR-JRTLPCBOSA-N 0.000 claims 1
- HPTJDALHSDQWKC-MPDHQVEESA-N 1-cyclopentyl-3-[(1r)-2-[(2s,4r)-2-[5-[4-[4-[2-[(2s,4r)-1-[(2r)-2-(cyclopentylcarbamoylamino)-2-phenylacetyl]-4-hydroxypyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-4-hydroxypyrrolidin-1-yl]-2-oxo-1-phenylethyl]urea Chemical compound N([C@@H](C(=O)N1[C@@H](C[C@H](C1)O)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(C[C@H](O)C1)C(=O)[C@H](NC(=O)NC1CCCC1)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)NC1CCCC1 HPTJDALHSDQWKC-MPDHQVEESA-N 0.000 claims 1
- RUJXBSVSFZKCEZ-ATUXXYJQSA-N 1-ethyl-3-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(ethylcarbamoylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]urea Chemical compound C1([C@@H](NC(=O)NCC)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)NCC)C=2C=CC=CC=2)=CC=CC=C1 RUJXBSVSFZKCEZ-ATUXXYJQSA-N 0.000 claims 1
- STZFHBJVOSTLJY-HEMKMFBASA-N 1-ethyl-3-[(1r)-2-[(2s,4r)-2-[5-[4-[4-[2-[(2s,4r)-1-[(2r)-2-(ethylcarbamoylamino)-2-phenylacetyl]-4-hydroxypyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-4-hydroxypyrrolidin-1-yl]-2-oxo-1-phenylethyl]urea Chemical compound C1([C@@H](NC(=O)NCC)C(=O)N2C[C@H](O)C[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](NC(=O)NCC)C=2C=CC=CC=2)=CC=CC=C1 STZFHBJVOSTLJY-HEMKMFBASA-N 0.000 claims 1
- NAVMQJJJBCMION-DNMDQSTESA-N 1-ethyl-3-[(1r)-2-oxo-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-1-phenylethyl]urea Chemical compound C([C@H]1C=2NC=C(N=2)C2=CC=C(C=C2)C2=CC=C(C=C2)C=2N=C(NC=2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)NCC)C=2C=CC=CC=2)CCN1C(=O)[C@H]1CCCO1 NAVMQJJJBCMION-DNMDQSTESA-N 0.000 claims 1
- IZWNAILWAKQOER-JPYDVTDNSA-N 1-methyl-3-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(methylcarbamoylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]urea Chemical compound C1([C@@H](NC(=O)NC)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)NC)C=2C=CC=CC=2)=CC=CC=C1 IZWNAILWAKQOER-JPYDVTDNSA-N 0.000 claims 1
- YLMQOWRZNAIITO-NCENMTFKSA-N 1-methyl-N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-[(1-methylpyrrolidine-2-carbonyl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]pyrrolidine-2-carboxamide Chemical compound CN1C(CCC1)C(=O)N[C@@H](C(=O)N1[C@@H](CCC1)C=1NC(=CN=1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@H]1N(CCC1)C([C@@H](C1=CC=CC=C1)NC(=O)C1N(CCC1)C)=O)C1=CC=CC=C1 YLMQOWRZNAIITO-NCENMTFKSA-N 0.000 claims 1
- 125000000980 1H-indol-3-ylmethyl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[*])C2=C1[H] 0.000 claims 1
- BWIPAGWNNPDQSR-QCSGVJIWSA-N 2-(4-hydroxypiperidin-1-yl)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[2-(4-hydroxypiperidin-1-yl)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1CC(O)CCN1C(C=1C=CC=CC=1)C(=O)N1[C@H](C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)C(N2CCC(O)CC2)C=2C=CC=CC=2)CCC1 BWIPAGWNNPDQSR-QCSGVJIWSA-N 0.000 claims 1
- QOFWQSWVNRCTHB-KYJUHHDHSA-N 2-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[2-(dimethylamino)acetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]ethanone Chemical compound CN(C)CC(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)CN(C)C)N1 QOFWQSWVNRCTHB-KYJUHHDHSA-N 0.000 claims 1
- VWMWKCWRUQWLOI-TWOGUARRSA-N 2-(dimethylamino)-n-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-[[2-(dimethylamino)acetyl]amino]-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]acetamide Chemical compound C1([C@@H](NC(=O)CN(C)C)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)CN(C)C)C=2C=CC=CC=2)=CC=CC=C1 VWMWKCWRUQWLOI-TWOGUARRSA-N 0.000 claims 1
- FNJVMYUPFVJPOQ-NSOVKSMOSA-N 2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]-4-[4-[4-[2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazole-5-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C2=C(NC(=N2)[C@H]2N(CCC2)C(=O)OC(C)(C)C)C(O)=O)N1 FNJVMYUPFVJPOQ-NSOVKSMOSA-N 0.000 claims 1
- GBUKZRAGCUOQQB-VXKWHMMOSA-N 2-[(2s)-pyrrolidin-2-yl]-5-[3-[3-[2-[(2s)-pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazole Chemical compound C1CCN[C@@H]1C1=NC=C(C=2C=C(C=CC=2)C=2C=C(C=CC=2)C=2N=C(NC=2)[C@H]2NCCC2)N1 GBUKZRAGCUOQQB-VXKWHMMOSA-N 0.000 claims 1
- UXYVOBIJTHABEM-VXKWHMMOSA-N 2-[(2s)-pyrrolidin-2-yl]-5-[4-[4-[2-[(2s)-pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazole Chemical compound C1CCN[C@@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2NCCC2)N1 UXYVOBIJTHABEM-VXKWHMMOSA-N 0.000 claims 1
- CHTIJJKUVTUKTB-QCSGVJIWSA-N 2-[benzyl(methyl)amino]-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[2-[benzyl(methyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)C(C(C)C)N(C)CC=1C=CC=CC=1)C(=O)C(C(C)C)N(C)CC1=CC=CC=C1 CHTIJJKUVTUKTB-QCSGVJIWSA-N 0.000 claims 1
- DDKBDVCMUUUCDO-ACHIHNKUSA-N 2-cyclopropyl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-(2-cyclopropylacetyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]ethanone Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)CC1CC1)C(=O)CC1CC1 DDKBDVCMUUUCDO-ACHIHNKUSA-N 0.000 claims 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- VMPMNBIAKKMDRM-UWXQCODUSA-N 2-phenyl-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-(2-phenylacetyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]ethanone Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)CC=1C=CC=CC=1)C(=O)CC1=CC=CC=C1 VMPMNBIAKKMDRM-UWXQCODUSA-N 0.000 claims 1
- HJSXUHQFFSCBRQ-CYAOVYSGSA-N 3-(dimethylamino)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]propan-1-one Chemical compound CN(C)CCC(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](N(C)C)C=2C=CC=CC=2)N1 HJSXUHQFFSCBRQ-CYAOVYSGSA-N 0.000 claims 1
- RSMGUARYIWRQQL-ATUXXYJQSA-N 3-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(dimethylcarbamoylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]-1,1-dimethylurea Chemical compound C1([C@@H](NC(=O)N(C)C)C(=O)N2CCC[C@H]2C=2NC=C(N=2)C2=CC=C(C=C2)C2=CC=C(C=C2)C=2N=C(NC=2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)N(C)C)C=2C=CC=CC=2)=CC=CC=C1 RSMGUARYIWRQQL-ATUXXYJQSA-N 0.000 claims 1
- CCCXMGQBMIIRCJ-UHFFFAOYSA-N 3-amino-3-phenylbutan-2-one Chemical compound CC(=O)C(C)(N)C1=CC=CC=C1 CCCXMGQBMIIRCJ-UHFFFAOYSA-N 0.000 claims 1
- JOWZRLXPCRELFD-TWOGUARRSA-N 3-methyl-n-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-[(3-methylimidazole-4-carbonyl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]imidazole-4-carboxamide Chemical compound CN1C=NC=C1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N1[C@H](C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](NC(=O)C=2N(C=NC=2)C)C=2C=CC=CC=2)CCC1 JOWZRLXPCRELFD-TWOGUARRSA-N 0.000 claims 1
- ZLUNOIGSIZFDGU-JRTLPCBOSA-N 4-methyl-n-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-[(4-methylpiperazine-1-carbonyl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]piperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N1[C@H](C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](NC(=O)N2CCN(C)CC2)C=2C=CC=CC=2)CCC1 ZLUNOIGSIZFDGU-JRTLPCBOSA-N 0.000 claims 1
- ZUSICOZTNLYPLS-VXKWHMMOSA-N 5-[2,5-difluoro-4-[4-[2-[(2s)-pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-2-[(2s)-pyrrolidin-2-yl]-1h-imidazole Chemical compound FC1=CC(C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2NCCC2)=C(F)C=C1C(N1)=CN=C1[C@@H]1CCCN1 ZUSICOZTNLYPLS-VXKWHMMOSA-N 0.000 claims 1
- DQLSZJFTUJORPP-JPYDVTDNSA-N 5-[2-[(2s)-1-[(2r)-2-(methoxycarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-2-[4-[2-[(2s)-1-[(2r)-2-(methoxycarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]benzoic acid Chemical compound C1([C@@H](NC(=O)OC)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C(=C2)C(O)=O)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)OC)C=2C=CC=CC=2)=CC=CC=C1 DQLSZJFTUJORPP-JPYDVTDNSA-N 0.000 claims 1
- AZYXVGFUHBAVAQ-PSWJWLENSA-N 5-[2-[(2s)-1-[(2r)-2-cyclopropyl-2-(methoxycarbonylamino)acetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-2-[4-[2-[(2s)-1-[(2r)-2-cyclopropyl-2-(methoxycarbonylamino)acetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]benzoic acid Chemical compound C1([C@@H](NC(=O)OC)C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C(=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@H](NC(=O)OC)C2CC2)C(O)=O)CC1 AZYXVGFUHBAVAQ-PSWJWLENSA-N 0.000 claims 1
- AZYXVGFUHBAVAQ-CUPIEXAXSA-N 5-[2-[(2s)-1-[(2s)-2-cyclopropyl-2-(methoxycarbonylamino)acetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-2-[4-[2-[(2s)-1-[(2s)-2-cyclopropyl-2-(methoxycarbonylamino)acetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]benzoic acid Chemical compound C1([C@H](NC(=O)OC)C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2C(=CC(=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C2CC2)C(O)=O)CC1 AZYXVGFUHBAVAQ-CUPIEXAXSA-N 0.000 claims 1
- NMOVRHCJJJXEBM-VXKWHMMOSA-N 5-[2-methoxy-5-[4-[2-[(2s)-pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-2-[(2s)-pyrrolidin-2-yl]-1h-imidazole Chemical compound COC1=CC=C(C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2NCCC2)C=C1C(N1)=CN=C1[C@@H]1CCCN1 NMOVRHCJJJXEBM-VXKWHMMOSA-N 0.000 claims 1
- KTEWNMWMUBUBQK-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.COC(N)=O Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.COC(N)=O KTEWNMWMUBUBQK-UHFFFAOYSA-N 0.000 claims 1
- VJEHYGQCKADVLY-IBGZPJMESA-N FC=1C=C(C=CC1C1=CN=CN1)C1=CC(=C(C=C1)C1=CN=C(N1)[C@H]1NCCC1)F Chemical compound FC=1C=C(C=CC1C1=CN=CN1)C1=CC(=C(C=C1)C1=CN=C(N1)[C@H]1NCCC1)F VJEHYGQCKADVLY-IBGZPJMESA-N 0.000 claims 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- JMQDAJUVBCGXQP-SSDOTTSWSA-N [(2R)-oxolan-2-yl]-(1,3-thiazolidin-3-yl)methanone Chemical compound C1CSCN1C(=O)[C@H]1CCCO1 JMQDAJUVBCGXQP-SSDOTTSWSA-N 0.000 claims 1
- VSQFWIIBMFLCJX-NSOVKSMOSA-N [(2s)-2-[5-[4-[4-[2-[(2s)-1-(1-hydroxycyclopropanecarbonyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-(1-hydroxycyclopropyl)methanone Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)C1(O)CC1)C(=O)C1(O)CC1 VSQFWIIBMFLCJX-NSOVKSMOSA-N 0.000 claims 1
- WHAMRSHSQGONQS-KYJUHHDHSA-N [(2s)-2-[5-[4-[4-[2-[(2s)-1-(cyclopropanecarbonyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-cyclopropylmethanone Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)C1CC1)C(=O)C1CC1 WHAMRSHSQGONQS-KYJUHHDHSA-N 0.000 claims 1
- WLUPZPAHCGZFHZ-GASGPIRDSA-N [(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-[(2r)-oxolan-2-yl]methanone Chemical compound N1([C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)[C@@H]1OCCC1)C(=O)[C@H]1CCCO1 WLUPZPAHCGZFHZ-GASGPIRDSA-N 0.000 claims 1
- PYOIEZITHVALJR-ZPGRZCPFSA-N [(2s)-2-[5-[4-[4-[2-[(2s)-1-benzoylpyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-phenylmethanone Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)C=2C=CC=CC=2)CCN1C(=O)C1=CC=CC=C1 PYOIEZITHVALJR-ZPGRZCPFSA-N 0.000 claims 1
- LPGQZYFEMJAUFM-VDUNKYASSA-N acetic acid 5-[2-fluoro-4-[4-[2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-2-[(2S)-pyrrolidin-2-yl]-1H-imidazole Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.FC1=CC(C=2C=CC(=CC=2)C=2NC(=NC=2)[C@H]2NCCC2)=CC=C1C(N1)=CN=C1[C@@H]1CCCN1 LPGQZYFEMJAUFM-VDUNKYASSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- IHIBPMKGKJSBKT-UHFFFAOYSA-N but-3-enyl carbamate Chemical compound NC(=O)OCCC=C IHIBPMKGKJSBKT-UHFFFAOYSA-N 0.000 claims 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 claims 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 claims 1
- RESUUPXKMFUBMD-LZCGGXSTSA-N n-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-(morpholine-4-carbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]morpholine-4-carboxamide Chemical compound N([C@@H](C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@H](NC(=O)N1CCOCC1)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)N1CCOCC1 RESUUPXKMFUBMD-LZCGGXSTSA-N 0.000 claims 1
- BTRAPGYMHCITQM-ATUXXYJQSA-N n-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-acetamido-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]acetamide Chemical compound C1([C@@H](NC(C)=O)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)C)C=2C=CC=CC=2)=CC=CC=C1 BTRAPGYMHCITQM-ATUXXYJQSA-N 0.000 claims 1
- MZMCBFFZRZHSDI-JPYDVTDNSA-N n-[(1r)-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-formamido-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]formamide Chemical compound C1([C@@H](NC=O)C(=O)N2CCC[C@H]2C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](NC=O)C=2C=CC=CC=2)=CC=CC=C1 MZMCBFFZRZHSDI-JPYDVTDNSA-N 0.000 claims 1
- XRLZRYGYLZMQML-FDYONOINSA-N n-[(1r)-2-oxo-1-phenyl-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-2-phenyl-2-[(2-pyridin-3-ylacetyl)amino]acetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]ethyl]-2-pyridin-3-ylacetamide Chemical compound N([C@@H](C(=O)N1[C@@H](CCC1)C=1NC(=CN=1)C=1C=CC(=CC=1)C=1C=CC(=CC=1)C=1NC(=NC=1)[C@H]1N(CCC1)C(=O)[C@H](NC(=O)CC=1C=NC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)CC1=CC=CN=C1 XRLZRYGYLZMQML-FDYONOINSA-N 0.000 claims 1
- CCOQRFXJBJDNQV-DNMDQSTESA-N n-[(1r)-2-oxo-2-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2r)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-1-phenylethyl]acetamide Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)C)C=2C=CC=CC=2)CCN1C(=O)[C@H]1CCCO1 CCOQRFXJBJDNQV-DNMDQSTESA-N 0.000 claims 1
- ULEZWUGQDAQWPT-UHFFFAOYSA-N n-ethylcyclopropanamine Chemical compound CCNC1CC1 ULEZWUGQDAQWPT-UHFFFAOYSA-N 0.000 claims 1
- DGOYLVBDCVINQZ-UHFFFAOYSA-N oxane-4-carboxamide Chemical compound NC(=O)C1CCOCC1 DGOYLVBDCVINQZ-UHFFFAOYSA-N 0.000 claims 1
- OVPLZYJGTGDFNB-UHFFFAOYSA-N propan-2-yl carbamate Chemical compound CC(C)OC(N)=O OVPLZYJGTGDFNB-UHFFFAOYSA-N 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims 1
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83699606P | 2006-08-11 | 2006-08-11 | |
| US60/836,996 | 2006-08-11 | ||
| US11/835,462 US8329159B2 (en) | 2006-08-11 | 2007-08-08 | Hepatitis C virus inhibitors |
| US11/835,462 | 2007-08-08 | ||
| PCT/US2007/075544 WO2008021927A2 (en) | 2006-08-11 | 2007-08-09 | Hepatitis c virus inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013064764A Division JP5769749B2 (ja) | 2006-08-11 | 2013-03-26 | Ｃ型肝炎ウイルス阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500413A JP2010500413A (ja) | 2010-01-07 |
| JP2010500413A5 true JP2010500413A5 (enExample) | 2010-05-27 |
| JP5235882B2 JP5235882B2 (ja) | 2013-07-10 |
Family
ID=38812845
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524736A Expired - Fee Related JP5235882B2 (ja) | 2006-08-11 | 2007-08-09 | Ｃ型肝炎ウイルス阻害剤 |
| JP2013064764A Expired - Fee Related JP5769749B2 (ja) | 2006-08-11 | 2013-03-26 | Ｃ型肝炎ウイルス阻害剤 |
| JP2015105694A Pending JP2015172064A (ja) | 2006-08-11 | 2015-05-25 | Ｃ型肝炎ウイルス阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013064764A Expired - Fee Related JP5769749B2 (ja) | 2006-08-11 | 2013-03-26 | Ｃ型肝炎ウイルス阻害剤 |
| JP2015105694A Pending JP2015172064A (ja) | 2006-08-11 | 2015-05-25 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US8329159B2 (enExample) |
| EP (5) | EP2385048A1 (enExample) |
| JP (3) | JP5235882B2 (enExample) |
| KR (2) | KR101450352B1 (enExample) |
| CN (1) | CN104447707B (enExample) |
| AR (1) | AR063684A1 (enExample) |
| AU (1) | AU2007286222B2 (enExample) |
| BR (1) | BRPI0716483B8 (enExample) |
| CA (1) | CA2660520C (enExample) |
| CL (1) | CL2007002327A1 (enExample) |
| CO (1) | CO6150171A2 (enExample) |
| CY (4) | CY1115594T1 (enExample) |
| DK (3) | DK2784075T3 (enExample) |
| EA (1) | EA015756B1 (enExample) |
| ES (3) | ES2476592T3 (enExample) |
| HR (3) | HRP20140737T1 (enExample) |
| HU (2) | HUE029145T2 (enExample) |
| IL (1) | IL196813A (enExample) |
| LT (2) | LT3042901T (enExample) |
| LU (1) | LU92635I2 (enExample) |
| MX (1) | MX2009001426A (enExample) |
| NL (1) | NL300713I2 (enExample) |
| NO (2) | NO340543B1 (enExample) |
| NZ (1) | NZ574805A (enExample) |
| PE (1) | PE20080542A1 (enExample) |
| PL (3) | PL2049522T3 (enExample) |
| PT (2) | PT3042901T (enExample) |
| SI (3) | SI3042901T1 (enExample) |
| TW (1) | TWI432426B (enExample) |
| WO (1) | WO2008021927A2 (enExample) |
| ZA (1) | ZA200900962B (enExample) |
Families Citing this family (240)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005319305B2 (en) | 2004-12-20 | 2012-08-23 | Genentech, Inc. | Pyrrolidine inhibitors of IAP |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010510245A (ja) * | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス化合物 |
| US8907092B2 (en) * | 2007-04-30 | 2014-12-09 | Genentech, Inc. | Inhibitors of IAP |
| MX2009011930A (es) | 2007-05-04 | 2009-11-18 | Vertex Pharma | Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c. |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ITMI20071012A1 (it) * | 2007-05-18 | 2008-11-19 | St Microelectronics Srl | Dispositivo di memoria migliorato a veloce programmazione |
| CN103450077B (zh) | 2007-06-08 | 2016-07-06 | 满康德股份有限公司 | IRE-1α抑制剂 |
| KR20150089099A (ko) * | 2007-07-05 | 2015-08-04 | 어레이 바이오파마 인크. | Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄 |
| US7728027B2 (en) * | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| NZ583970A (en) | 2007-10-11 | 2011-04-29 | Univ California | Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase |
| JP2011511841A (ja) | 2008-02-12 | 2011-04-14 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| JP5314053B2 (ja) * | 2008-02-12 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PL2242752T3 (pl) * | 2008-02-13 | 2012-12-31 | Bristol Myers Squibb Co | Imidazolilobifenyloimidazole jako inhibitory wirusa zapalenia wątroby typu c |
| NZ590550A (en) | 2008-08-02 | 2013-05-31 | Genentech Inc | Inhibitors of Apoptosis (IAP) for treating cancer |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI480272B (zh) * | 2008-10-09 | 2015-04-11 | Anadys Pharmaceuticals Inc | 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法 |
| PL2373172T3 (pl) * | 2008-12-03 | 2013-12-31 | Presidio Pharmaceuticals Inc | Inhibitory HCV NS5A |
| JP2012510523A (ja) | 2008-12-03 | 2012-05-10 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
| SG172353A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| WO2010091413A1 (en) * | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8420686B2 (en) | 2009-02-17 | 2013-04-16 | Enanta Pharmaceuticals, Inc. | Linked diimidazole antivirals |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8637561B2 (en) | 2009-02-17 | 2014-01-28 | Enanta Pharmaceuticals, Inc. | Linked diimidazole derivatives |
| TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US20120040977A1 (en) * | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| UY32462A (es) | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US10752611B2 (en) | 2009-02-27 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8426458B2 (en) | 2009-02-27 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Hepatitis C Virus inhibitors |
| WO2010099527A1 (en) * | 2009-02-27 | 2010-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| KR20110131312A (ko) * | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 ｃ형 간염 억제제 |
| EP2410841A4 (en) | 2009-03-27 | 2012-10-24 | Presidio Pharmaceuticals Inc | SUBSTITUTED BICYCLIC HCV INHIBITORS |
| TWI476190B (zh) * | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) * | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9278922B2 (en) * | 2009-04-15 | 2016-03-08 | Abbvie Inc. | Anti-viral compounds |
| BRPI1016172A2 (pt) * | 2009-04-24 | 2016-04-19 | Tibotec Pharm Ltd | éteres diarílicos |
| AU2010249080A1 (en) * | 2009-05-12 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| KR101503752B1 (ko) | 2009-05-13 | 2015-03-18 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| AU2013202666B2 (en) * | 2009-05-13 | 2015-07-16 | Gilead Sciences, Inc. | Antiviral compounds |
| AU2014203349B2 (en) * | 2009-05-13 | 2014-11-27 | Gilead Sciences, Inc. | Antiviral compounds |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2435424B1 (en) * | 2009-05-29 | 2015-01-21 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2010253790A1 (en) * | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| US8691938B2 (en) * | 2009-06-11 | 2014-04-08 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| AU2012203474B2 (en) * | 2009-06-11 | 2014-09-18 | Abbvie Ireland Unlimited Company | Anti-Viral Compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| JP2012533569A (ja) | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| AU2010280711A1 (en) * | 2009-08-07 | 2012-02-09 | Janssen Sciences Ireland Uc | Phenyl ethynyl derivatives as hepatitis C virus inhibitors |
| CN102471324B (zh) * | 2009-08-07 | 2014-12-17 | 泰博特克药品公司 | 作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物 |
| RU2012112824A (ru) | 2009-09-03 | 2013-10-10 | Тиботек Фармасьютикалз | Производные бис-бензимидазола |
| CA2771327A1 (en) | 2009-09-04 | 2011-03-10 | Glaxosmithkline Llc | Chemical compounds |
| WO2011031934A1 (en) * | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CA2782024A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US20110137633A1 (en) * | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Anti-viral compounds and methods of identifying the same |
| EP2507232B1 (en) * | 2009-12-04 | 2019-03-20 | National Health Research Institutes | Proline derivatives |
| WO2011081918A1 (en) | 2009-12-14 | 2011-07-07 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PH12012501216A1 (en) * | 2009-12-18 | 2012-11-05 | Boehringer Ingelheim Int | Hcv combination therapy |
| CN104341401B (zh) * | 2009-12-18 | 2017-02-15 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| AR079528A1 (es) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
| WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| MX2012007420A (es) * | 2009-12-24 | 2012-07-23 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones de flavivirus. |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2528436A4 (en) | 2010-01-25 | 2013-07-10 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2528926A4 (en) * | 2010-01-28 | 2013-06-19 | Boehringer Ingelheim Int | HEPATITIS C INHIBITOR COMPOUNDS |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| JP2013521279A (ja) | 2010-03-04 | 2013-06-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖ複製の阻害剤としての医薬併用剤 |
| KR20130008040A (ko) | 2010-03-09 | 2013-01-21 | 머크 샤프 앤드 돔 코포레이션 | 융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법 |
| WO2011119870A1 (en) * | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| EP2550268A1 (en) * | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
| WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US9125904B1 (en) | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| WO2011146401A1 (en) * | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| EP2575866A4 (en) * | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| NZ605440A (en) * | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| JP2013531011A (ja) | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
| JP2013529684A (ja) | 2010-06-28 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
| WO2012009394A2 (en) * | 2010-07-16 | 2012-01-19 | Bristol-Myers Squibb Company | Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication |
| JP2013541499A (ja) | 2010-07-26 | 2013-11-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法 |
| BR112013002122A2 (pt) | 2010-07-26 | 2016-09-20 | Janssen R&D Ireland | derivados hetero-bicíclicos como inibidores de hcv |
| US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| US8697704B2 (en) | 2010-08-12 | 2014-04-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| AR082619A1 (es) | 2010-08-13 | 2012-12-19 | Hoffmann La Roche | Inhibidores del virus de la hepatitis c |
| EP2606041A2 (en) | 2010-08-17 | 2013-06-26 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
| WO2012027712A2 (en) * | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis c virus |
| WO2012040389A2 (en) | 2010-09-22 | 2012-03-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
| CN103249730A (zh) * | 2010-09-24 | 2013-08-14 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US8999967B2 (en) | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
| JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
| JP5909495B2 (ja) | 2010-10-08 | 2016-04-26 | ノバルティス アーゲー | スルファミドｎｓ３阻害剤のビタミンｅ製剤 |
| ES2560842T3 (es) * | 2010-10-13 | 2016-02-23 | Abbvie Bahamas Ltd. | Un derivado de 1-fenil-2,5-dibenzimidazol-5-il-pirrolidina antiviral |
| AU2014203655B2 (en) * | 2010-10-13 | 2016-07-07 | Abbvie Ireland Unlimited Company | Anti-viral compounds |
| WO2012048421A1 (en) * | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| BR112013009789A2 (pt) | 2010-10-26 | 2016-07-19 | Presidio Pharmaceuticals Inc | inibidores do vírus da hepatite c |
| WO2012061552A1 (en) | 2010-11-04 | 2012-05-10 | Theravance, Inc. | Novel inhibitors of hepatitis c virus |
| CA3102625C (en) * | 2010-11-17 | 2024-02-20 | Gilead Pharmasset Llc | Antiviral compounds |
| EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
| RU2452735C1 (ru) | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
| WO2012083061A2 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| WO2012083048A2 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| CN106986862A (zh) | 2010-12-22 | 2017-07-28 | Abbvie 公司 | 丙型肝炎抑制剂及其用途 |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| US8835456B1 (en) | 2011-03-18 | 2014-09-16 | Achillion Pharmaceuticals, Inc. | NS5A inhibitors useful for treating HCV |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2012158861A2 (en) | 2011-05-18 | 2012-11-22 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives |
| EA029099B1 (ru) | 2011-05-27 | 2018-02-28 | Ачиллион Фармасьютикалз, Инк. | Замещенные циклофаны для использования при лечении инфекции вгс |
| WO2012175581A1 (en) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| WO2013016501A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Formulations of thiophene compounds |
| WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
| AU2012298750A1 (en) * | 2011-08-24 | 2014-03-13 | Glaxosmithkline Llc | Combination treatments for Hepatitis C |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| SG10201602044WA (en) | 2011-09-16 | 2016-04-28 | Gilead Pharmassett Llc | Methods For Treating HCV |
| GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2847083A1 (en) | 2011-10-10 | 2013-04-18 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| TWI532487B (zh) | 2011-10-21 | 2016-05-11 | 艾伯維有限公司 | 治療ｃ型肝炎病毒（ｈｃｖ）之方法 |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| DE112012003457T5 (de) | 2011-10-21 | 2015-03-12 | Abbvie Inc. | Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV) |
| KR20140091036A (ko) * | 2011-11-03 | 2014-07-18 | 세라밴스 인코포레이티드 | 단편 [2-[4-(바이페닐-4-일)-1h-이미다조-2-일]피롤리딘-1-카르보닐메틸]아민을 포함하는 간상 c형 간염 바이러스 억제제 |
| HUE027733T2 (en) | 2011-11-16 | 2016-10-28 | Gilead Pharmasset Llc | Condensed imidazolylimidazoles as antiviral compounds |
| WO2013078430A1 (en) | 2011-11-22 | 2013-05-30 | The Regents Of The University Of California | Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa) |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| MX2014006745A (es) | 2011-12-16 | 2014-10-15 | Hoffmann La Roche | Inhibidores de hcv ns5a. |
| PT2794629T (pt) | 2011-12-20 | 2017-07-20 | Riboscience Llc | Derivados de nucleósidos substituídos em 2¿-4¿-difluor-2¿-metilo, como inibidores da replicação do arn de vhc (vírus da hepatite c) |
| LT2794628T (lt) | 2011-12-20 | 2017-07-10 | Riboscience Llc | 4`-azido-3`-fluoro pakeistieji nukleozido dariniai kaip hcv replikacijos inhibitoriai |
| MX348127B (es) | 2011-12-28 | 2017-05-26 | Janssen Sciences Ireland Uc | Derivados de quinazolinona como inhibidores del virus de la hepatitis c. |
| US9126986B2 (en) | 2011-12-28 | 2015-09-08 | Janssen Sciences Ireland Uc | Hetero-bicyclic derivatives as HCV inhibitors |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) * | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US9090559B2 (en) | 2012-02-24 | 2015-07-28 | Hoffmann-La Roche Inc. | Antiviral compounds |
| EP2827876A4 (en) | 2012-03-22 | 2015-10-28 | Alios Biopharma Inc | PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG |
| JP6069491B2 (ja) | 2012-04-25 | 2017-02-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｃ型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物 |
| CN104302636B (zh) | 2012-04-25 | 2017-03-29 | 施万生物制药研发Ip有限责任公司 | C型肝炎病毒抑制剂 |
| US8883135B2 (en) | 2012-05-03 | 2014-11-11 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
| US20150252028A1 (en) * | 2012-10-24 | 2015-09-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| KR20150109451A (ko) | 2013-01-23 | 2015-10-01 | 에프. 호프만-라 로슈 아게 | 항바이러스성 트라이아졸 유도체 |
| AU2014202687A1 (en) | 2013-01-31 | 2014-08-14 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| RU2507201C1 (ru) | 2013-02-07 | 2014-02-20 | Александр Васильевич Иващенко | Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| KR20150114566A (ko) | 2013-03-05 | 2015-10-12 | 에프. 호프만-라 로슈 아게 | 항바이러스 화합물 |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| WO2014144836A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| WO2014144547A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| WO2014175699A1 (ko) | 2013-04-26 | 2014-10-30 | 서울대학교 산학협력단 | 벤지딘 유도체, 이의 제조방법 및 이를 함유하는 c형 간염 바이러스에 의한 간질환 치료용 약학적 조성물. |
| WO2014186637A1 (en) | 2013-05-16 | 2014-11-20 | Riboscience Llc | 4'-fluor0-2'-methyl substituted nucleoside derivatives |
| SG11201509427RA (en) | 2013-05-16 | 2015-12-30 | Riboscience Llc | 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives |
| US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2015026454A1 (en) * | 2013-07-17 | 2015-02-26 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus |
| US20160158200A1 (en) * | 2013-07-09 | 2016-06-09 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| SI3038601T1 (sl) | 2013-08-27 | 2020-07-31 | Gilead Pharmasset Llc | Formulacija kombinacije dveh protivirusnih spojin |
| KR101561964B1 (ko) | 2013-11-15 | 2015-10-20 | 한국과학기술연구원 | 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물 |
| US20160311806A1 (en) * | 2013-12-11 | 2016-10-27 | Bristol-Myers Squibb Company | 4,4'-biphenyldiyl-bis-(1 h-imidazolyl) derivatives as hepatitis hcv inhibitors |
| WO2015089810A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| AP2016009496A0 (en) | 2014-04-04 | 2016-10-31 | X-Rx Inc | Substituted spirocydic inhibitors of autotaxin |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| EP3166852B1 (en) | 2014-07-08 | 2018-03-28 | GIMA S.p.A. | Unit and method for filling containing elements of single-use capsules for extraction or infusion beverages. |
| WO2016075588A1 (en) * | 2014-11-11 | 2016-05-19 | Sun Pharmaceutical Industries Limited | Stable amorphous daclatasvir dihydrochloride |
| WO2016089814A1 (en) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Deuterated analogues of daclatasvir |
| CN105753944B (zh) * | 2014-12-19 | 2019-10-01 | 正大天晴药业集团股份有限公司 | 达卡他韦及其衍生物的制备中间体 |
| WO2016102979A1 (en) | 2014-12-26 | 2016-06-30 | Cipla Limited | Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof |
| CN106188015B (zh) * | 2015-05-06 | 2019-10-18 | 广东东阳光药业有限公司 | 一种制备达卡他韦的方法 |
| WO2016178250A1 (en) | 2015-05-07 | 2016-11-10 | Mylan Laboratories Limited | Process for the preparation of daclatasvir |
| CZ2015366A3 (cs) | 2015-05-29 | 2016-12-07 | Zentiva, K.S. | Pevné formy Daclatasviru |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2017076358A1 (zh) * | 2015-11-06 | 2017-05-11 | 苏州晶云药物科技有限公司 | 咪唑基联苯基化合物盐的新晶型及其制备方法 |
| GB2552919A (en) * | 2015-11-18 | 2018-02-21 | Azad Pharmaceutical Ingredients Ag | Stable amorphous form of daclatasvir |
| CN106083829B (zh) * | 2016-01-12 | 2019-01-22 | 深圳市塔吉瑞生物医药有限公司 | 一种丙型肝炎病毒抑制剂、药物组合物及其应用 |
| US11186541B2 (en) * | 2016-03-28 | 2021-11-30 | The University Of Toledo | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| CN109689063A (zh) | 2016-04-28 | 2019-04-26 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
| US20190256498A1 (en) | 2016-07-08 | 2019-08-22 | Lupin Limited | Crystalline forms of daclatasvir dihydrochloride |
| WO2018015847A1 (en) * | 2016-07-18 | 2018-01-25 | Glenmark Pharmaceuticals Limited | Process for preparation of daclatasvir and salts |
| CN108069941A (zh) * | 2016-11-15 | 2018-05-25 | 广东东阳光药业有限公司 | 一种制备达卡他韦的方法 |
| RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| US10392370B2 (en) * | 2017-03-13 | 2019-08-27 | Optimus Drugs Pvt Ltd | Process for the preparation of Daclatasvir dihydrochloride and its intermediates |
| MX2019011173A (es) | 2017-03-22 | 2020-01-09 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c. |
| CN109305962B (zh) * | 2017-07-28 | 2022-01-18 | 扬子江药业集团有限公司 | 一种盐酸达拉他韦的精制方法 |
| TWI860279B (zh) | 2017-09-21 | 2024-11-01 | 美商里伯賽恩斯有限責任公司 | 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物 |
| WO2020117849A1 (en) | 2018-12-04 | 2020-06-11 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
| TW202106677A (zh) * | 2019-04-25 | 2021-02-16 | 美商貝達醫藥公司 | 用於治療c型肝炎病毒感染之ns5a的二胺甲酸酯抑制劑 |
| CR20230467A (es) | 2021-03-10 | 2024-02-20 | Jnana Therapeutics Inc | Inhibidores de molécula pequeña de la función de slc6a19 de mamífero |
| KR20240012476A (ko) | 2021-05-21 | 2024-01-29 | 길리애드 사이언시즈, 인코포레이티드 | 지카 바이러스 저해제로서의 펜타사이클릭 유도체 |
| CA3219397A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| EP4587021A1 (en) * | 2022-09-14 | 2025-07-23 | Jnana Therapeutics Inc. | Treating pku with correctors of mammalian slc6a19 function |
| WO2025122482A1 (en) * | 2023-12-04 | 2025-06-12 | Henry Ford Health System | Methods and compositions to inhibit tribbles 2 for cancer therapy |
| CN119707774A (zh) * | 2024-12-24 | 2025-03-28 | 浙江工业大学 | 一种微波辅助1,5,6,7-四氢-4h-吲哚-4-酮衍生物的溴化方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994015909A1 (en) | 1993-01-14 | 1994-07-21 | Magainin Pharmaceuticals, Inc. | Amino acids and peptides having modified terminals |
| US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
| WO1998027108A2 (en) * | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| CN1476428A (zh) * | 2000-09-22 | 2004-02-18 | �ݶ�ũ�����ѧ�ɷݹ�˾ | 用作农药的△1-吡咯啉类化合物 |
| US20040142993A1 (en) | 2002-07-01 | 2004-07-22 | Carlo Battistini | Inhibitors of HCV NS5B polymerase |
| WO2004005264A2 (en) | 2002-07-05 | 2004-01-15 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
| US7183302B2 (en) | 2002-08-12 | 2007-02-27 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of HCV replication |
| DE10243939A1 (de) * | 2002-09-24 | 2004-04-01 | Bayer Cropscience Ag | Pyrroline |
| US7220745B2 (en) * | 2003-05-15 | 2007-05-22 | Rigel Pharmaceuticals | Heterocyclic compounds useful to treat HCV |
| US20050119318A1 (en) * | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
| GB0326168D0 (en) | 2003-11-10 | 2003-12-17 | Arrow Therapeutics Ltd | Chemical compounds |
| US7514434B2 (en) * | 2004-02-23 | 2009-04-07 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof |
| WO2005105761A1 (en) | 2004-04-28 | 2005-11-10 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
| AU2005275183B2 (en) * | 2004-07-26 | 2011-03-17 | Eli Lilly And Company | Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2006093867A1 (en) | 2005-02-28 | 2006-09-08 | The Rockefeller University | Structure of the hepatitits c virus ns5a protein |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| PL1940786T3 (pl) | 2005-09-16 | 2010-12-31 | Arrow Therapeutics Ltd | Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C |
| WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| US7915411B2 (en) | 2005-12-21 | 2011-03-29 | Abbott Laboratories | Anti-viral compounds |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| RU2008132806A (ru) | 2006-01-11 | 2010-02-20 | Арроу Терапьютикс Лимитед (Gb) | Производные триазолоанилинопиримидина для применения в качестве противовирусных средств |
| WO2007082554A1 (en) | 2006-01-23 | 2007-07-26 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Modulators of hcv replication |
| BRPI0712806A2 (pt) | 2006-05-30 | 2012-10-23 | Arrow Therapeutics Ltd | uso de um composto, derivado de bifenila ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, produto, e, método para melhorar uma infecção por hepatite c em um paciente |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7745636B2 (en) * | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8629171B2 (en) * | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US8181098B2 (en) * | 2008-06-11 | 2012-05-15 | Freescale Semiconductor, Inc. | Error correcting Viterbi decoder |
| TWI476190B (zh) * | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20120196794A1 (en) * | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| US8552047B2 (en) * | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2007
- 2007-08-08 US US11/835,462 patent/US8329159B2/en not_active Expired - Fee Related
- 2007-08-09 PT PT161530449T patent/PT3042901T/pt unknown
- 2007-08-09 HU HUE14168065A patent/HUE029145T2/hu unknown
- 2007-08-09 PE PE2007001068A patent/PE20080542A1/es active IP Right Grant
- 2007-08-09 AR ARP070103535A patent/AR063684A1/es active IP Right Grant
- 2007-08-09 BR BRPI0716483A patent/BRPI0716483B8/pt not_active IP Right Cessation
- 2007-08-09 DK DK14168065.2T patent/DK2784075T3/en active
- 2007-08-09 EP EP11171390A patent/EP2385048A1/en not_active Withdrawn
- 2007-08-09 NZ NZ574805A patent/NZ574805A/en unknown
- 2007-08-09 SI SI200732006T patent/SI3042901T1/en unknown
- 2007-08-09 EP EP17189589.9A patent/EP3321263A3/en not_active Withdrawn
- 2007-08-09 JP JP2009524736A patent/JP5235882B2/ja not_active Expired - Fee Related
- 2007-08-09 KR KR1020097004970A patent/KR101450352B1/ko not_active Expired - Fee Related
- 2007-08-09 CL CL200702327A patent/CL2007002327A1/es unknown
- 2007-08-09 ES ES07800058.5T patent/ES2476592T3/es active Active
- 2007-08-09 PT PT78000585T patent/PT2049522E/pt unknown
- 2007-08-09 MX MX2009001426A patent/MX2009001426A/es active IP Right Grant
- 2007-08-09 TW TW096129384A patent/TWI432426B/zh not_active IP Right Cessation
- 2007-08-09 AU AU2007286222A patent/AU2007286222B2/en not_active Ceased
- 2007-08-09 PL PL07800058T patent/PL2049522T3/pl unknown
- 2007-08-09 DK DK07800058.5T patent/DK2049522T3/da active
- 2007-08-09 LT LTEP16153044.9T patent/LT3042901T/lt unknown
- 2007-08-09 PL PL14168065.2T patent/PL2784075T3/pl unknown
- 2007-08-09 SI SI200731498T patent/SI2049522T1/sl unknown
- 2007-08-09 KR KR1020147010437A patent/KR101475189B1/ko not_active Expired - Fee Related
- 2007-08-09 HR HRP20140737TT patent/HRP20140737T1/hr unknown
- 2007-08-09 SI SI200731764A patent/SI2784075T1/sl unknown
- 2007-08-09 EP EP07800058.5A patent/EP2049522B1/en not_active Not-in-force
- 2007-08-09 WO PCT/US2007/075544 patent/WO2008021927A2/en not_active Ceased
- 2007-08-09 EP EP16153044.9A patent/EP3042901B1/en not_active Not-in-force
- 2007-08-09 EP EP14168065.2A patent/EP2784075B1/en not_active Not-in-force
- 2007-08-09 PL PL16153044T patent/PL3042901T3/pl unknown
- 2007-08-09 HU HUE16153044A patent/HUE037802T2/hu unknown
- 2007-08-09 EA EA200900298A patent/EA015756B1/ru active Protection Beyond IP Right Term
- 2007-08-09 CA CA2660520A patent/CA2660520C/en not_active Expired - Fee Related
- 2007-08-09 ES ES16153044.9T patent/ES2662590T3/es active Active
- 2007-08-09 ES ES14168065.2T patent/ES2573523T3/es active Active
- 2007-08-09 CN CN201410607190.3A patent/CN104447707B/zh not_active Expired - Fee Related
- 2007-08-09 DK DK16153044.9T patent/DK3042901T3/en active
-
2009
- 2009-01-29 NO NO20090447A patent/NO340543B1/no not_active IP Right Cessation
- 2009-02-01 IL IL196813A patent/IL196813A/en active Protection Beyond IP Right Term
- 2009-02-10 ZA ZA2009/00962A patent/ZA200900962B/en unknown
- 2009-02-11 CO CO09013323A patent/CO6150171A2/es unknown
-
2012
- 2012-10-12 US US13/650,374 patent/US8642025B2/en not_active Expired - Fee Related
-
2013
- 2013-03-26 JP JP2013064764A patent/JP5769749B2/ja not_active Expired - Fee Related
- 2013-09-18 US US14/030,199 patent/US8900566B2/en not_active Expired - Fee Related
-
2014
- 2014-08-12 CY CY20141100644T patent/CY1115594T1/el unknown
- 2014-09-17 US US14/488,990 patent/US9227961B2/en not_active Expired - Fee Related
-
2015
- 2015-01-14 LU LU92635C patent/LU92635I2/xx unknown
- 2015-01-20 NL NL300713C patent/NL300713I2/nl unknown
- 2015-02-03 LT LTPA2015006C patent/LTC2049522I2/lt unknown
- 2015-02-20 CY CY2015004C patent/CY2015004I2/el unknown
- 2015-05-25 JP JP2015105694A patent/JP2015172064A/ja active Pending
- 2015-11-06 US US14/934,538 patent/US9421192B2/en not_active Expired - Fee Related
-
2016
- 2016-04-19 HR HRP20160410TT patent/HRP20160410T8/hr unknown
- 2016-06-15 CY CY20161100534T patent/CY1117641T1/el unknown
- 2016-06-28 US US15/194,980 patent/US9758487B2/en not_active Expired - Fee Related
-
2017
- 2017-07-20 US US15/654,905 patent/US10047056B2/en not_active Expired - Fee Related
- 2017-07-28 NO NO2017036C patent/NO2017036I1/no unknown
-
2018
- 2018-02-28 CY CY20181100254T patent/CY1119988T1/el unknown
- 2018-03-26 HR HRP20180496TT patent/HRP20180496T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500413A5 (enExample) | ||
| HRP20140737T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2010500414A5 (enExample) | ||
| JP2013510853A5 (enExample) | ||
| HRP20120706T1 (hr) | Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c | |
| JP2011530531A5 (enExample) | ||
| CN103030636B (zh) | 丙型肝炎病毒的大环抑制剂 | |
| JP2012518000A5 (enExample) | ||
| JP2010500415A5 (enExample) | ||
| HRP20120440T1 (hr) | Inhibitori virusa hepatitisa c | |
| JP2014513690A5 (enExample) | ||
| JP2012522053A5 (enExample) | ||
| JP2012522056A5 (enExample) | ||
| ES2564906T3 (es) | Inhibidores de NS5A del VHC | |
| HRP20130063T1 (hr) | Inhibitori virusa hepatitisa c | |
| JP2013532725A5 (enExample) | ||
| US20120039847A1 (en) | Hepatitis C Virus Inhibitors | |
| PT1912997E (pt) | Inibidores macrocíclicos do vírus da hepatite c | |
| NZ600608A (en) | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors | |
| JP2013510857A5 (enExample) | ||
| JP2004504317A5 (enExample) | ||
| AR065331A1 (es) | Derivados de bifenilil-1h-imidazol y bifenildiil-bis(1h-imidazol-4,2)diilo como inhibidores del virus de la hepatitis c, composiciones que los comprenden y su uso en el tratamiento de una infeccion de vhc. | |
| HK1126486B (en) | Hepatitis c virus inhibitors | |
| HK1174897A (zh) | 丙型肝炎病毒的大环抑制剂 | |
| HK1174897B (en) | Macrocyclic inhibitors of hepatitis c virus |